BioCentury
ARTICLE | Clinical News

Bristol-Myers reports more data for all-oral HCV regimen

April 24, 2013 1:05 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) reported data on Tuesday from a Phase IIa trial evaluating an oral regimen of twice-daily asunaprevir, once-daily daclatasvir and twice-daily BMS-791325 to treat HCV genotype 1 infection in treatment-naïve, non-cirrhotic patients. In the first part of the trial, a 24-week regimen produced a sustained virologic response (SVR) 12 weeks after end of treatment in 94% of patients. The SVR24 rate was 88%. A 12-week regimen led to an SVR24 rate of 94% and an SVR36 rate of 88%. In the second part of the trial, a 12-week regimen led to an SVR12 rate of 89%, with one relapse and one virologic breakthrough. Patients received 75 mg BMS-791325 in the first part of the trial and 150 mg in the second part. Data are slated to be presented this week at the European Association for the Study of the Liver meeting in Amsterdam. ...